These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38886852)

  • 1. Immune checkpoint inhibitor-induced cardiotoxicity in patients with lung cancer: a systematic review and meta-analysis.
    Yamani N; Ahmed A; Ruiz G; Zubair A; Arif F; Mookadam F
    Cardiooncology; 2024 Jun; 10(1):37. PubMed ID: 38886852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis.
    Zhang XT; Ge N; Xiang ZJ; Liu T
    Cancer Cell Int; 2022 Nov; 22(1):363. PubMed ID: 36402980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
    Agostinetto E; Eiger D; Lambertini M; Ceppi M; Bruzzone M; Pondé N; Plummer C; Awada AH; Santoro A; Piccart-Gebhart M; de Azambuja E
    Eur J Cancer; 2021 May; 148():76-91. PubMed ID: 33740500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials.
    Jin C; Qi J; Wang Q; Pu C; Tan M
    Front Oncol; 2023; 13():1158690. PubMed ID: 37124488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta-Analysis of Observational Studies and Randomized Controlled Trials.
    Sharma A; Alexander G; Chu JH; Markopoulos A; Maloul G; Ayub MT; Fidler MJ; Okwuosa TM
    J Am Heart Assoc; 2024 May; 13(10):e032620. PubMed ID: 38761070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemo-Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Banna GL; Hassan MA; Signori A; Giunta EF; Maniam A; Anpalakhan S; Acharige S; Ghose A; Addeo A
    JAMA Netw Open; 2024 Apr; 7(4):e246837. PubMed ID: 38625698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis.
    Farooq MZ; Aqeel SB; Lingamaneni P; Pichardo RC; Jawed A; Khalid S; Banskota SU; Fu P; Mangla A
    JAMA Netw Open; 2022 Apr; 5(4):e227722. PubMed ID: 35438755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis.
    Yang W; Men P; Xue H; Jiang M; Luo Q
    Front Oncol; 2020; 10():197. PubMed ID: 32211312
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
    Liu S; Gao W; Ning Y; Zou X; Zhang W; Zeng L; Liu J
    Front Immunol; 2022; 13():908173. PubMed ID: 35880172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Yan X; Tian X; Wu Z; Han W
    Front Oncol; 2020; 10():1671. PubMed ID: 33072551
    [No Abstract]   [Full Text] [Related]  

  • 16. Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
    Pala L; Sala I; Oriecuia C; De Pas T; Queirolo P; Specchia C; Cocorocchio E; Ferrucci P; Patanè D; Saponara M; Pennacchioli E; Coppola S; Viale G; Giaccone G; Gelber RD; Bagnardi V; Conforti F
    JAMA Netw Open; 2022 Aug; 5(8):e2226252. PubMed ID: 35972744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
    Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Yu X; Zhang X; Yao T; Zhang Y; Zhang Y
    Front Med (Lausanne); 2021; 8():627089. PubMed ID: 33659263
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials.
    Liu H; Luo SX; Jie J; Peng L; Wang S; Song L
    Front Immunol; 2023; 14():1115305. PubMed ID: 36926326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer.
    Chitturi KR; Xu J; Araujo-Gutierrez R; Bhimaraj A; Guha A; Hussain I; Kassi M; Bernicker EH; Trachtenberg BH
    JACC CardioOncol; 2019 Dec; 1(2):182-192. PubMed ID: 34396181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.